Suggested remit: To appraise the clinical and cost effectiveness of bimatoprost slow-release biodegradable implant within its marketing authorisation for people with open angle glaucoma or ocular hypertension who are unsuitable for topical intraocular pressure lowering treatments
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6180

Project Team

Project lead Louise Jafferally

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 September 2024 Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
09 August 2024 - 30 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
21 July 2023 - 18 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6180
09 August 2023 Please note that following on from advice received from the company this appraisal has been scheduled to align with latest regulatory expectations. Therefore, the appraisal will begin in Q1 2024 when we will write to you about how you can get involved.
31 March 2023 In progress. DHSC referral received
15 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual